242 related articles for article (PubMed ID: 28815894)
1. Challenges of developing and conducting clinical trials in rare disorders.
Kempf L; Goldsmith JC; Temple R
Am J Med Genet A; 2018 Apr; 176(4):773-783. PubMed ID: 28815894
[TBL] [Abstract][Full Text] [Related]
2. The future of Cochrane Neonatal.
Soll RF; Ovelman C; McGuire W
Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
[TBL] [Abstract][Full Text] [Related]
3. Patient-Reported Outcome and Observer-Reported Outcome Assessment in Rare Disease Clinical Trials: An ISPOR COA Emerging Good Practices Task Force Report.
Benjamin K; Vernon MK; Patrick DL; Perfetto E; Nestler-Parr S; Burke L
Value Health; 2017; 20(7):838-855. PubMed ID: 28712612
[TBL] [Abstract][Full Text] [Related]
4. Recommendations for the design of small population clinical trials.
Day S; Jonker AH; Lau LPL; Hilgers RD; Irony I; Larsson K; Roes KC; Stallard N
Orphanet J Rare Dis; 2018 Nov; 13(1):195. PubMed ID: 30400970
[TBL] [Abstract][Full Text] [Related]
5. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
6. Rare cancer trial design: lessons from FDA approvals.
Gaddipati H; Liu K; Pariser A; Pazdur R
Clin Cancer Res; 2012 Oct; 18(19):5172-8. PubMed ID: 22718862
[TBL] [Abstract][Full Text] [Related]
7. Post-approval Studies for Rare Disease Treatments and Orphan Drugs.
Maier WC; Christensen RA; Anderson P
Adv Exp Med Biol; 2017; 1031():197-205. PubMed ID: 29214573
[TBL] [Abstract][Full Text] [Related]
8. Regulatory strategies for rare diseases under current global regulatory statutes: a discussion with stakeholders.
Mulberg AE; Bucci-Rechtweg C; Giuliano J; Jacoby D; Johnson FK; Liu Q; Marsden D; McGoohan S; Nelson R; Patel N; Romero K; Sinha V; Sitaraman S; Spaltro J; Kessler V
Orphanet J Rare Dis; 2019 Feb; 14(1):36. PubMed ID: 30736861
[TBL] [Abstract][Full Text] [Related]
9. Dose-finding studies in drug development for rare genetic diseases.
Wang L; Wang J; Feng J; Doi M; Pepe S; Pacanowski M; Schuck RN
Orphanet J Rare Dis; 2022 Apr; 17(1):156. PubMed ID: 35382851
[TBL] [Abstract][Full Text] [Related]
10. Navigating the Regulatory Landscape to Develop Pediatric Oncology Drugs: Expert Opinion Recommendations.
Barry E; Walsh JA; Weinrich SL; Beaupre D; Blasi E; Arenson DR; Jacobs IA
Paediatr Drugs; 2021 Jul; 23(4):381-394. PubMed ID: 34173206
[TBL] [Abstract][Full Text] [Related]
11. [The stakes of pre- and post-market authorization development and clinical assessment].
Schwebig A
Presse Med; 2012 May; 41 Suppl 1():S6-8. PubMed ID: 22483770
[No Abstract] [Full Text] [Related]
12. Strategies for postmarketing surveillance of drugs for rare diseases.
Kesselheim AS; Gagne JJ
Clin Pharmacol Ther; 2014 Mar; 95(3):265-8. PubMed ID: 24193169
[TBL] [Abstract][Full Text] [Related]
13. Preparing for the Future of Rare Diseases.
Groft SC; Posada de la Paz M
Adv Exp Med Biol; 2017; 1031():641-648. PubMed ID: 29214596
[TBL] [Abstract][Full Text] [Related]
14. Effective Market Exclusivity of New Molecular Entities for Rare and Non-rare Diseases.
Kerr KW; Glos LJ
Pharmaceut Med; 2020 Feb; 34(1):19-29. PubMed ID: 32048213
[TBL] [Abstract][Full Text] [Related]
15. FDA orphan products clinical trial grants: assessment of outcomes and impact on rare disease product development.
Miller KL; Mueller C; Liu G; Miller Needleman KI; Maynard J
Orphanet J Rare Dis; 2020 Sep; 15(1):234. PubMed ID: 32883327
[TBL] [Abstract][Full Text] [Related]
16. Characteristics of non-randomised studies using comparisons with external controls submitted for regulatory approval in the USA and Europe: a systematic review.
Goring S; Taylor A; Müller K; Li TJJ; Korol EE; Levy AR; Freemantle N
BMJ Open; 2019 Feb; 9(2):e024895. PubMed ID: 30819708
[TBL] [Abstract][Full Text] [Related]
17. Statistical considerations for rare diseases drug development.
Chow SC; Chang YW
J Biopharm Stat; 2019; 29(5):874-886. PubMed ID: 31454299
[TBL] [Abstract][Full Text] [Related]
18. Incentives for orphan drug research and development in the United States.
Seoane-Vazquez E; Rodriguez-Monguio R; Szeinbach SL; Visaria J
Orphanet J Rare Dis; 2008 Dec; 3():33. PubMed ID: 19087348
[TBL] [Abstract][Full Text] [Related]
19. Need to improve clinical trials in rare neurodegenerative disorders.
Puopolo M; Pocchiari M
Ann Ist Super Sanita; 2011; 47(1):55-9. PubMed ID: 21430340
[TBL] [Abstract][Full Text] [Related]
20. A checklist for clinical trials in rare disease: obstacles and anticipatory actions-lessons learned from the FOR-DMD trial.
Crow RA; Hart KA; McDermott MP; Tawil R; Martens WB; Herr BE; McColl E; Wilkinson J; Kirschner J; King WM; Eagle M; Brown MW; Hirtz D; Lochmuller H; Straub V; Ciafaloni E; Shieh PB; Spinty S; Childs AM; Manzur AY; Morandi L; Butterfield RJ; Horrocks I; Roper H; Flanigan KM; Kuntz NL; Mah JK; Morrison L; Darras BT; von der Hagen M; Schara U; Wilichowski E; Mongini T; McDonald CM; Vita G; Barohn RJ; Finkel RS; Wicklund M; McMillan HJ; Hughes I; Pegoraro E; Bryan Burnette W; Howard JF; Thangarajh M; Campbell C; Griggs RC; Bushby K; Guglieri M
Trials; 2018 May; 19(1):291. PubMed ID: 29793540
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
